Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This significant milestone enhances our global regulatory standing
The Q1 2025 also witnessed a successful launch of Allegra D
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
